Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.65 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.56 |
| ▸ | DTYMK | P23919 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24864688 | 1.00 | POLB (0.69) | POLBENPP1P2RY1RNASELDTYMK | |
| SCHEMBL31454757 | 0.94 | POLB (0.70) | POLBENPP1P2RY1RNASELADORA1 | |
| SCHEMBL29382612 | 0.94 | POLB (0.70) | POLBENPP1P2RY1RNASELADORA1 | |
| SCHEMBL17269644 | 0.93 | POLB (0.60) | POLBENPP1P2RY1RNASELDTYMK | |
| SCHEMBL17268345 | 0.93 | POLB (0.60) | POLBENPP1P2RY1RNASELDTYMK | |
| SCHEMBL10034040 | 0.92 | POLB (0.72) | POLBENPP1P2RY1RNASELDTYMK | |
| SCHEMBL10034046 | 0.91 | POLB (0.66) | POLBENPP1P2RY1DTYMKADORA1 | |
| SCHEMBL29677728 | 0.91 | POLB (0.63) | POLBENPP1P2RY1DTYMK | |
| SCHEMBL29868797 | 0.91 | POLB (0.63) | POLBENPP1P2RY1DTYMK | |
| SCHEMBL21447399 | 0.91 | POLB (0.56) | POLBENPP1P2RY1RNASELADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118620223-A | Metal organic framework Cu-MOF fluorescent probe and application thereof in rapid detection of erythromycin in water | 浙江工业大学 | 2024-09-10 | — | — | CN | claimed |
| EP-3718551-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3812761-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4053179-B1 | CROSSLINKED POLY(ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | RENOSIS INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250011276-A1 | PROCESS FOR THE PREPARATION OF 1,3-BIS(ALLYLAMINO)PROPANE | RENIBUS THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20240384261-A1 | METHODS, COMPOSITIONS, AND KITS FOR PREPARING SEQUENCING LIBRARY | GENEFIRST LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| CN-118755098-A | Method for rapidly detecting dichromate ions in water based on Zr-MOF fluorescent probe | 浙江工业大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-118620223-A | Metal organic framework Cu-MOF fluorescent probe and application thereof in rapid detection of erythromycin in water | 浙江工业大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-118620223-A | Metal organic framework Cu-MOF fluorescent probe and application thereof in rapid detection of erythromycin in water | 浙江工业大学 | 2024-09-10 | — | — | CN | disclosed |
| US-20240254267-A1 | CROSSLINKED POLY (ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | RENIBUS THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20230405043-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENIBUS THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11738041-B2 | Proton-binding polymers for oral administration | RENOSIS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230201235-A1 | INHIBITION OF NIDOVIRUSES THAT ENCODE NSP15 | THE UNIVERSITY OF CHICAGO (US) | 2023-06-29 | — | — | US | disclosed |
| CN-116211887-A | Composition for treating acid-base imbalance | 特里赛达公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022263807-A1 | METHODS, COMPOSITIONS, AND KITS FOR PREPARING SEQUENCING LIBRARY | GENEFIRST LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| US-20220339186-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENIBUS THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022186813-A1 | CROSSLINKED POLY(ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | TRICIDA, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4053179-A1 | CROSSLINKED POLY(ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | Tricida Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11311571-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220096534-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENIBUS THERAPEUTICS, INC. | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339186-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | SLC9A1, HRH2, SLC9A2 | POLB 1439/4885ENPP1 1202/4885P2RY1 1026/4885 |
| US-20230201235-A1 | INHIBITION OF NIDOVIRUSES THAT ENCODE NSP15 | TYMP, TYMS, ISG15 | POLB 77/4885ENPP1 344/4885P2RY1 2110/4885 |
| US-20250011276-A1 | PROCESS FOR THE PREPARATION OF 1,3-BIS(ALLYLAMINO)PROPANE | PBRM1, APEX1, AP1M1 | POLB 101/4885ENPP1 1347/4885P2RY1 2634/4885 |
| US-11738041-B2 | Proton-binding polymers for oral administration | SLC9A1, HRH2, SLC9A2 | POLB 1439/4885ENPP1 1202/4885P2RY1 1026/4885 |
| US-20240254267-A1 | CROSSLINKED POLY (ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | PARG, PARN, AAAS | POLB 1871/4885ENPP1 991/4885P2RY1 2130/4885 |
| US-20230405043-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | SLC9A1, HRH2, SLC9A2 | POLB 1439/4885ENPP1 1202/4885P2RY1 1026/4885 |
| US-11311571-B2 | Proton-binding polymers for oral administration | SLC9A1, HRH2, SLC9A2 | POLB 1439/4885ENPP1 1202/4885P2RY1 1026/4885 |
| US-20220096534-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | SLC9A1, HRH2, SLC9A2 | POLB 1439/4885ENPP1 1202/4885P2RY1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.